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levels of inflammatory cytokines or serum uric acid or their changes. Serum uric acid and
its changes independently predict poor prognosis in CHF, more acurately than do plasma
cytokines.
1163-120 Complement Activation in Patients With Congestive 
Heart Failure
Suhua Wu, Hong Ma, Yugang Dong, Jiangui He, Huiying Ye, Yujun Zhong, First Affiliated 
Hospital, Sun Yet-Sen University, Guangzhou, People's Republic of China
Background Increasing evidence suggests that complement may play a role in the
pathogenesis of myocardial damage secondary to ischemia and reperfusion, but the role
of complement in congestive heart failure is at present unclear. Objectives To determine
whether the complement system is activated and its relationship to clinical outcomes in
patients with congestive heart failure (CHF). Methods The plasma levels of products of
complement activation C4d (classic pathway), Bb (alternative pathway), 3bc (final com-
mon pathway) and C5b-9 (terminal complement complex) were measured by enzyme-
linked immunosorbent assay(ELISA) method in forty-four patients with CHF and sixteen
normal age and sex matched volunteers. The left ventricular ejection fractions of all
patients were measured by electron beam computed tomography (EBCT). Forty-one
patients with CHF were followed up for 13±3 months to determine the combined clinical
outcomes (hospitalization with worsening heart failure or death). Results Our major find-
ing were (1) The plasma levels of C4d, Bb, C3bc and C5b-9 in patients with CHF were
significantly higher than those in normal volunteers. (2) Significantly more of the patients
with highest levels of C5b-9 ( highest 50th percentile ) had worse left ventricular function
and adverse clinical outcomes compared with the patients with lowest levels of C5b-9 (
lowest 50th percentile). Conclusions We have observed an activation of complement
system and an association between high levels of C5b-9 and adverse clinical events in
patients with CHF. Our findings suggested that complement might be added to the list of
possible therapeutic targets.
1163-121 Prognostic Role of Neutrophil and Lymphocyte Counts 
in Heart Failure: Results From Val-HeFT
Inder S. Anand, Joseph Yen, Viorel G. Florea, Allen Hester, Robert Glazer, Roberto 
Latini, Aldo Maggioni, Jay N. Cohn, Veterans Affairs Medical Center and University of 
Minnesota, Minneapolis, MN
Background. Lymphocyte and neutrophil counts predict cardiovascular events in patients
with coronary artery disease. Their role in heart failure (HF), however, is not known. We
evaluated the prognostic value of baseline (BL) neutrophil and lymphocyte counts on
mortality and first morbid event (M&M;) in the Valsartan Heart Failure Trial (Val-HeFT).
Methods and Results. Blood counts were measured at BL and during follow-up. Cox pro-
portional hazards analysis was made for all cause mortality and M&M; with BL neutrophil
and lymphocyte counts, classified by median and quartile (Q) groupings and used as
independent variables in separate analyses. Patients with high BL neutrophil counts and
low BL lymphocyte counts had more advanced HF. Both neutrophil and lymphocyte
counts were significant multivariate predictors of mortality and M&M; when analyzed as
continuous, dichotomized or Q variables. Whereas, higher neutrophil count was associ-
ated with greater mortality and M&M;, higher BL lymphocyte count was associated with a
lower mortality and M&M;. Relative risk (RR) for neutrophils was 1.315 (95% CI 1.172 –
1.458; p=0.00016) and for lymphocytes 0.789 (95% CI 0.644 – 0.934, p=0.00131). Com-
parison of RRs and 95 % CIs with other dichotomized (> vs < median) multivariate pre-
dictors of mortality in descending order of p-value is shown in Table.
Conclusions: High BL neutrophil and low BL lymphocyte counts are important predictors
of outcomes in HF, suggesting a possible role of inflammation in the progression of HF.
1163-122 Does Wider QRS Reflect Heart Failure Severity?
Teresa De Marco, Michael B. Higginbotham, Leslie A. Saxon, Sudha Balasubramanian, 
Patrick Yong, Elyse Foster, University of California San Francisco, San Francisco, CA, 
Guidant Corporation, St. Paul, MN
Background: A wide QRS is used as a surrogate measure of ventricular dysynchrony for
selecting cardiac resynchronization therapy candidates. It is not clear if prolonged QRS
correlates with other baseline measures such as left ventricular structure, systolic func-
tion, exercise tolerance, and heart failure symptoms.
Methods: Patients participating in the VENTAK® CHF/CONTAK® CD Biventricular Pac-
ing Study were included in this retrospective analysis. Correlation of baseline QRS was
calculated for each of the following baseline parameters: left ventricular ejection fraction
(LVEF), LV internal dimension, systole (LVIDs), peak oxygen consumption (peak VO2),
six-minute walk distance (6MWD), quality of life (QOL; Minnesota living with heart failure
questionnaire) and NYHA class.
Results: At implant the study population consisted of 83% males, mean age 66 ± 10
years, NYHA II (33%), III (58%), IV (9%), mean LVEF 21±7%, mean QRS width 158 ± 28
ms. Baseline QRS significantly correlated with baseline LVEF, LVIDs, peak VO2, 6MWD
but not with QOL and NYHA Class.
Conclusions: Widening of the QRS is significantly associated with measures of heart
failure severity including greater LV dimension, lower LVEF and reduced exercise toler-
ance but does not correlate with measures of symptomatic status. If these findings can
be confirmed, then the degree of QRS prolongation in heart failure patients may serve as
an inexpensive and reliable surrogate indicator of these measures of heart failure sever-
ity.
1163-123 Relationship Between Plasma C-Reactive Protein 
Concentration on Admission and Long-Term Outcome 
in Unselected Hospitalized Heart Failure Patients
Colin Berry, Karen Hogg, Karen Stevenson, John Norrie, John J. McMurray, University of 
Glasgow, Glasgow, United Kingdom
Background: Although systemic inflammation is recognised in heart failure (HF) its impor-
tance in relation to outcome is uncertain. Plasma c-reactive protein (pCRP) concentration
is typically elevated in inflammatory conditions and is recognised as a marker of systemic
inflammation.
Methods: We studied all index emergency admissions with HF to one University hospital
(which provides exclusive acute medical care to the local urban district) during the year
2000. Echocardiography was undertaken by a single operator. Reduced LVSF was
defined as an ejection fraction of <40%. Hematological and biochemical data (from the
initial blood samples taken on the day of admission) were obtained from hospital elec-
tronic records. Information on death was obtained from the national record linkage data-
base for all patients.
Results: 528 consecutive first admissions with HF were identified. The median follow-up
was 693 days (range 1 - 978 days). Median (interquartile range) pCRP concentration was
16 (5, 183) mg/L, and 65% of patients had an elevated (> 10 mg/L) pCRP concentration.
45% and 35% of patients had a pCRP concentration greater than 20 and 30 mg/L,
respectively. Univariate predictors of an elevated pCRP concentration included hemoglo-
bin, hematocrit, white cell count (WCC), platelet count, serum creatinine concentration
and plasma fibrinogen, sodium and albumin concentrations. On multivariate analysis,
predictors (odds ratio, 95% CI) of pCRP concentration included WCC (1.9 [1.4, 2.9]),
fibrinogen count (1.9 [1.3, 2.6]), and albumin (0.7 [0.5, 0.9]). pCRP concentration was an
independent predictor of in-hospital survival (Cox proportional hazard ratio (HR) 0.2 per
SD (61 mg/L); 95% CI 0.1,0.6, P=0.001), and long-term mortality (CRP per SD, HR 1.4;
95% CI 1.2 -1.7; P <0.001 ).
Conclusion: Systemic inflammation, indicated by an elevated pCRP concentration, is
very common in hospitalized HF patients, and predicts long-term adverse outcome. That
CRP is an independent predictor of mortality suggests that this protein may have harmful
effects.
1163-124 Improvement in Autonomic Dysfunction Manifested by 
Altered Heart Rate Variability, T-Wave-Alternans and 
Norepinephrine by Long-Term Exercise in Chronic Heart 
Failure
Robert M. Nechwatal, Michael Horn, Uwe Scharf, Bettina Mochalski, Ulrike 
Lachenmeyer, Christiaan Barnard Klinik, Dahlen, Germany
Background: In recent years exercise training has become an established therapy for
patients with stable chronic heart failure. However there is a paucity of data on the effects
of long term training on autonomic dysfunction. Methods: 100 patients with DCM and
CHD were randomized to an exercise (n=50, mean age:49,9+-9,3,mean ejection fraction
(EF) 33,3+-5,7%)or to a control group (n=50, mean age:54,7+-11,3,EF: 32,4+-
5,3%).Patients underwent six 20 minute supervised training sessions per week at a VO2
of 60% VO2peak. Before and after the six month study period exercise testing with respi-
ratory gas exchange, heart rate variability in the time domain on holter monitoring, nore-
pinephrine plasma values and T-wave alternans testing were performed. Results:See
Table.VO2AT: oxygen uptake at the anaerobic threshold. *: p<0,05 **: p<0,01 vs pre-
training.id: indeterminate. 10 patients in the exercise group and 2 in the control group did
not complete the protocol: one of each group died unassociated with exercise, one of
Table (for changes over time between drugs: all p>0.2)
Time point TNF sTNFR1 IL-6 IL1-RA Uric Acid
(pg/mL) (pg/mL) (pg/mL) (pg/mL) (mg/dL)
Carvedilol-BL 2.20±0.14 1575±79 3.25±0.30 400±25 7.26±0.24
Carvedilol-FU 2.13±0.22 1615±72 3.53±0.32 406±27 7.47±0.23
Placebo-BL 1.92±0.11 1589±59 3.26±0.25 410±39 7.24±0.23
Placebo-FU 1.96±0.26 1621±80 3.84±0.32 409±30 7.11±0.25
Variable BNP NYHA, III 
and IV
LVIDD/
BSA
Uric 
Acid
Neutrop
hils
Plasma 
Renin 
Activity
Beta 
Blocke
r Use
Lympho
cytes
Norepin
ephrine
Age, 
>65 yrs
Ischem
ic 
etiolog
y
Creatini
ne
Relative 
Risk
1.906 1.398 1.354 1.357 1.315 1.324 0.754 0.789 1.272 1.260 1.208 1.206
95% CI 1.748, 
2.065
1.257, 
1.539
1.211, 
1.497
1.206, 
1.508
1.172, 
1.458
1.177, 
1.471
0.597, 
0.910
0.644, 
0.934
1.125, 
1.419
1.113, 
1.407
1.059, 
1.357
1.053, 
1.358
p-Value <0.00001 <0.00001 0.00003 0.00007 0.00016 0.00018 0.0004 0.00131 0.00132 0.00216 0.0123 0.01701
Variable
 N  Correlation  P-value
LVEF at Baseline
 500  -0.17  <0.01
LVIDs at Baseline
 420  0.27  <0.01
Peak VO2 at Baseline
 382  -0.11  0.03
6 MWD at Baseline
 438  -0.12  0.02
QOL at Baseline
 457  0.03  0.59
NYHA at Baseline
 465  0.08  0.10
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each group developed atrial fibrillation, one had a CABG and seven stopped for compli-
ance reasons. Conclusions: Long term training in stable heart failure is a safe means to
improve functional capacity and autonomic dysfunction. Mean heart rate, norepinephrine
and SDNN were improved significantly,the last even more pronounced in the subgroup
with SDNN<100. The conversion of a positive TWA-test in 6 patients in the training group
could used for therapeutic intervention.
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1164-125 Development of Murine Fibrotic Cardiomyopathy Is 
Dependent on Monocyte Chemoattractant Protein 1
Oliver Dewald, Guofeng Ren, Christina Klemm, Kim Winkelmann, Anna Koerting, George 
Taffet, Lloyd H. Michael, Mark L. Entman, Nikolaos G. Frangogiannis, Baylor College of 
Medicine, Houston, TX
Background: Repetitive brief myocardial ischemia and reperfusion (I/R) is implicated in
the pathogenesis of ventricular dysfunction in ischemic cardiomyopathy and myocardial
hibernation. In a murine model of repetitive brief I/R, we reported a reversible fibrotic car-
diomyopathy in the absence of myocardial infarction, resembling the pathomorphology of
human hibernating myocardium. Much like regional dysfunction in patients, repetitive
brief murine I/R was accompanied by induction of the chemokine Monocyte Chemoat-
tractant Protein (MCP)-1. Accordingly, we examined the role of MCP-1 in the pathogene-
sis of murine cardiomyopathy.
Methods: C57/Bl6 mice undergoing daily 15 min coronary occlusions followed by reper-
fusion, received i.p. MCP-1 neutralizing antibody, or vehicle, after the end of each
ischemia episode. After echocardiographic examination, hearts were processed for histo-
logical and RNA studies.
Results: After 3-5 days of repetitive I/R, chemokine induction in ischemic hearts was
accompanied by interstitial macrophage infiltration. After 7 days of repetitive I/R, marked
interstitial fibrosis was noted in the ischemic area, accompanied by echocardiographic
evidence of global ventricular dysfunction and segmental hypocontractility of the anterior
wall. MCP-1 neutralization did not affect macrophage infiltration in the ischemic myocar-
dium, but significantly inhibited interstitial fibrosis (anterior wall, collagen-stained area,
vehicle 21.5±6.6 % vs. MCP-1 antibody 12.9±2.8 %, P<0.05). Also, MCP-1 inhibition
attenuated left ventricular dysfunction (fractional shortening, 35.1±1.2 % vs. 42.6±1.7 %,
P<0.05) and decreased regional hypocontractility (anterior wall thickening, 35.7±2.4 %
vs. 60.9±3.0 %, P<0.05). MCP-1 antibody-treated mice showed decreased expression of
the matricellular protein Osteopontin 1, a marker of tissue remodeling, after 3 days of I/R.
Conclusion: MCP-1 plays a crucial role in the pathogenesis of murine ischemic cardi-
omyopathy through effects, which appear to be independent of its leukotactic properties.
Endogenous expression of MCP-1 may be important in regulating fibrosis in patients with
ischemic cardiomyopathy.
1164-126 Characteristics of Duchenne and Becker Muscular 
Dystrophy Patients in the Pediatric Cardiomyopathy 
Registry
David Connuck, Lynn Sleeper, Jeffrey Towbin, Steven Colan, Gerald Cox, Leigha 
Cuniberti, John Orav, Bonnie Anne Salbert, Steven Lipshultz, University of Rochester, 
Rochester, NY, New England Research Institutes, Watertown, MA
Background: The NHLBI-sponsored PCMR is a multicenter study of pediatric cardiomy-
opathy (CM) in North America. Data have been collected on patients with Duchenne
(DMD) and Becker (BMD) muscular dystrophy.
Methods: As of May 2003, the Registry is comprised of 2,602 children and adolescents
who presented to a pediatric cardiologist with CM from 1990 to present. Inclusion criteria
include 1) <18.0 years at time of CM diagnosis; 2) echocardiographic evidence of CM,
defined as >2 left ventricular measurements (ejection fraction, posterior wall thickness,
septal thickness, end diastolic dimension or volume) exceeding 2 SD or an echocardio-
graphic pattern of CM; or 3) a pathologic diagnosis of CM on autopsy or endomyocardial
biopsy; or 4) other clinical evidence provided by the cardiologist.
Results: The PCMR includes 134 patients with DMD or BMD. 99% are male, 27% are
non-white. We observed 39 DMD and 1 BMD deaths; 0 DMD transplants and 6 BMD
transplants, for a total of 39 DMD and 7 BMD death/transplant events. 25% of all DMD
patients die within 2.2 years following CM diagnosis (defined as meeting PCMR entry cri-
teria) and 50% die within 5.3 years (p=.219 vs. BMD). 25% of all BMD pts die or are
transplanted within 0.4 years following CM diagnosis and 50% die or are transplanted
within 1.3 years (p=.063 vs. DMD). At diagnosis patients with BMD are somewhat more
likely (p=.143) to have mitral regurgitation (60% vs. 24%), particularly those with conges-
tive heart failure (100% vs. 40%), and a higher LV end diastolic dimension(3.0 vs. 1.3
BSA-adjusted Z-score, p=.002) than patients with DMD. Similarities between the two
groups include a mean age of CM diagnosis of 14 years, with 1/3 having congestive
heart failure at enrollment. Non-muscular dystrophy patients in the PCMR have a lower
mortality rate than the BMD/DMD group (p<0.0001).
Conclusions: Current observations suggest that the DMD/BMD groups have different
clinical characteristics at the time of CM diagnosis, with mitral regurgitation, LV dilation
and heart failure being more common in the BMD patients. Following diagnosis for CM,
DMD patients have a higher mortality rate and BMD patients may have a higher trans-
plant rate than pediatric patients with other types of CM.
1164-127 Whole Body, Myocardial, and Coronary Vascular Insulin 
Resistance in Conscious Dogs With Pacing Induced 
Dilated Cardiomyopathy
Amy Schuett, Lazaros A. Nikolaidis, Teresa Hentosz, Carol Stolarski, Aaron Doverspike, 
Rhonda Huerbin, Lee Zourelias, Richard P. Shannon, Dariush Elahi, Allegheny General 
Hospital, Pittsburgh, PA
Background: Previous work from our laboratory has demonstrated reduced basal myo-
cardial glucose uptake in conscious dogs with advanced DCM as they transition to a dec-
ompensated state. The cellular basis of the impaired glucose uptake involves impaired
GLUT-4 translocation. Our goal was to determine whether the development of insulin
resistance in DCM was limited to the myocardium or involved whole body insulin resis-
tance and whether the impaired action of insulin extended beyond its metabolic effects.
Methods: We studied 8 conscious, chronically instrumented dogs under normal fasting
circumstances before (Con) and after the development of advanced DCM induced by 4-5
weeks of rapid pacing using the hyperinsulinemic-euglycemic clamp technique (480
pmol•m-2•min-1). We measured whole body and myocardial glucose uptake and vascu-
lar and hemodynamic responses to hyperinsulinemia.
Results: The development of DCM was associated with significant (*p<0.05) increases in
plasma norepinephrine levels (Con: 125±26; DCM: 378±42 pg/ml*), plasma insulin (Con:
27±4; DCM: 72±6 pmol/L*) and NEFA (Con: 236±43; DCM: 612±59 µmol/ l*). Plasma
insulin levels were raised acutely to 1100 pmol/L and plasma glucose clamped at 5 mM
for 120 minutes. Within 30 min., NEFA fell to < 50 µmol/L in both groups. Whole body glu-
cose disposition was less in DCM (52±3 µmol•kg-1•min-1*) compared to Con (66±3
µmol•kg-1•min-1). Myocardial glucose uptake increased in both groups during hyperin-
sulinemia, but to a lesser extent in DCM (1.6 ±0.4 to 4.2±1.1 µmol/min*) than Con (2.3
±0.6 to 13.1±3.1 µmol/min). Hyperinsulinemia was associated with significant increases
in coronary blood flow in Con (20±3 to 31±5 ml*), but had no effect in DCM (20±2 to 22
±2 ml).
Conclusions: With DCM, myocardial and total peripheral glucose uptake is reduced due
to overall insulin resistance. Insulin mediated suppression of NEFA remains intact. Insulin
resistance is also evident in the impaired vascular response to hyperinsulinemia in DCM.
1164-128 Endothelial Function of the Coronary Microcirculation Is 
Impaired in Patients With Myocardial Virus Persistence
Katja B. Vallbracht, Peter L. Schwimmbeck, Uwe Kuehl, Bettina Seeberg, Heinz-Peter 
Schultheiss, Charité Medical University, Benjamin Franklin Hospital, Berlin, Germany
Background
Myocardial virus persistence can be associated with myocardial inflammation and endot-
helial activation. The aim of this study is to investigate the impact of myocardial virus per-
sistence on endothelial function (ENF) of the coronary microcirculation.
Methods
In 71 patients with suspected cardiomyopathy, myocardial biopsies were examined for
virus persistence (PCR) and inflammation (immunohistology). Endothelial function of the
coronary microcirculation was examined during heart catheterization, measuring diame-
ter (QCA) and velocity changes (intracoronary doppler) of the mid LAD in response to
locally administered acetylcholine. Coronary blood flow was calculated (CBF). Endothe-
lium independent vasoreactivity to adenosine was assessed.
Results
Mean age of the 37 male and 34 female patients was 43+-13 years, ejection fraction was
64+-11%. In 42 patients, adeno-, entero-, parvo- or HHV6-virus was detected via PCR,
29 patients had no virus. ENF of the coronary microcirculation was significantly impaired
in patients with myocardial virus persistence, as compared to controls: dCBF-V 25+-85%,
dCBF-Co 103+-118% (p=0.004). In 51 patients, myocardial inflammation was detected
by immunohistology (InfCM), of those, 31 had virus persistence, 20 had no virus. dCBF
was significantly impaired in patients with myocardial virus persistence, as compared to
controls: dCBF-InfCM-V 16+-88%, dCBF-InfCM-Co 72+-114% (p=0.101). In 20 patients,
immunohistology of the myocardial biopsies were normal (Co), of those, 11 had virus per-
sistence and 9 had no virus. dCBF was impaired in patients with myocardial virus persis-
tence, as compared to controls: dCBF-Co-V 51+-72%, dCBF-Co-Co 175+-97 (p=0.006).
Endothelium independent vasodilation was not influenced significantly.
Conclusions
Exercise group Control group
pre post pre post
VO2AT
ml/min/kg
11,5+-1,9 14,0+-2,5** 12,3+-2,7 11,9+-2,5
VO2peak
ml/min/kg
18,4+-4,5 21,7+-4,5** 18,7+-4,6 17,7+-4,3
mean HR
beats
78,6+-12,2 71,8+-11,4* 72,4+-10,3 76,5+-10,2
norepinehrine
ng/l
592,3+-336,1 431,4+-215,0* 487,1+-381,6 713,4+-487,9**
SDNN 102,4+-50,6 117,3+-37,9* 105,2+-37,0 108,2+-41,3
RMSSD 25,7+-23,4 32,3+-26,1 31,2+-29,7 27,9+-24,4
SDANN 90,2+-43,5 101,9+-35,4 90,5+-29,0 96,5+-38,2
SDNN<100 70,1+-20,0 101,0+-27,4** 75,4+-20,4 85,0+-35,1
TWA positive 15 8 / 1 id * 18 17 / 1 id
